Author

Josianne Nitcheu

ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY
ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Josianne Nitcheu  et al.

ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS
ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS

Josianne Nitcheu  et al.

Item 1 - 2 / 2
1